PD-1/PD-L1抑制剂在晚期非小细胞肺癌治疗的研究进展

Progress of PD-1/PD-L1 inhibitors in treatment of advanced NSCLC

近几年来以程序性死亡受体-1(PD-1)/及程序性死亡配体-1(PD-L1)抑制剂为代表的免疫治疗取得了很大进展,已成为医学史上里程碑式的事件。在黑色素瘤、肺癌、肾癌及尿路上皮癌等恶性肿瘤的应用中,表现出令人鼓舞的疗效。本文对PD-1/PD-L1抑制剂在晚期非小细胞肺癌中的应用研究进行综述,旨在为晚期NSCLC的免疫治疗提供依据。

In recent years,immunotherapy,represented by programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1) inhibitors,has made great progress and become a milestone in medical history.In the application of malignant tumors such as melanoma,lung cancer,renal cancer and urothelial cancer,it has shown encouraging results.The application of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer is reviewed in order to provide evidence for immunotherapy of advanced NSCLC.